UNSPSC 51313212: Bamipine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H24N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4K9380352I, chemically known as piperidine, 4-(n-benzyl-n-phenylamino)-1-methyl-, dihydrochloride but more generally known as bamipine hydrochloride, which bears US NIH Compound Identifier 109130. European Medicines Agency schedules Bamipine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00662MIG.

Most nations, for tariff and trade purposes, schedule bamipine hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, BAMIPINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CCC(CC1)N(CC2CCCCC2)C3CCCCC3.CL.

UNSPSC 51313212 Bamipine hydrochloride is a Commodity code that nominally identifies a single pharmaceutical compound, but recent state and local solicitations show little activity specifically targeting this substance. The recent opportunities posted under this code diverge significantly from its narrow scope: Seminole County, Florida solicited naloxone and drug deactivation systems through a competitive IFB; Texas HHS issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) sought generic multi-source pharmaceuticals and OTC products through a cooperative purchasing vehicle. These opportunities indicate that state and local bodies are procuring pharmaceuticals and drug-related systems broadly, not bamipine hydrochloride specifically. The issuing bodies reflect a mix of county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The mismatch between the code's product-specific name and the actual solicitation scope suggests that either the code is underutilized for its intended purpose or is being applied inconsistently to broader pharmaceutical procurement categories.

The most recent activity appears concentrated in Florida and Minnesota, with secondary activity in Texas. Seminole County's IFB for naloxone and safe drug deactivation systems (posted June 30, 2026, due July 26, 2023) represents a direct county health initiative with quarterly deliveries required to the Seminole County Community Health Building; the contract includes a two-year initial term with one-year renewal options and is potentially FEMA-funded. MMCAP's RFP for generic pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) spans multiple participating states including Minnesota and Oregon, requiring distribution through three authorized wholesalers and awarding based on price competitiveness (75 percent weighting) among other factors, with a two-year contract term effective July 1, 2026. Texas HHS's RFI on direct-to-manufacturer prescriptions (posted April 3, 2026) functions as a market-intelligence tool rather than a binding solicitation, designed to inform future RFP strategy. The code shows minimal decision-relevant recent activity targeting bamipine hydrochloride itself.